ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Phase III results move Aimmune’s peanut allergy drug closer to EU market
March 28, 2019Aimmune has announced the results from its Phase III European clinical trials for AR101, the company’s investigational oral biologic drug designed to help protect patients from severe allergic reactions in case they are accidentally exposed to peanut.
Pharma Sources Insight January 2025
